
The German chemicals group lifted its adjusted EBITDA range, while analysts flagged a softer fourth-quarter outlook and BASF discussed Evonik.
BASF raised its 2026 adjusted EBITDA target after third-quarter operating profit beat analyst expectations. The company now expects adjusted EBITDA of €7.4 billion to €7.8 billion, up from its previous range of €6.9 billion to €7.7 billion.
Operating profit reached €1.64 billion in the quarter, compared with €1.43 billion a year earlier. Revenue rose 14.2% to €16.36 billion, supported by higher prices and sales volumes. BASF said Chemicals and Nutrition & Care made the strongest contributions.
Net profit attributable to shareholders fell nearly 10% to €155 million, partly because of restructuring costs, including employee severance payments. BASF kept its full-year free cash flow forecast at €1.5 billion to €2.3 billion.
The shares traded at €52.57, up 0.86% from the previous close, as of 16:09 UTC on Wednesday. Jefferies and JPMorgan analysts said BASF’s outlook pointed to fourth-quarter operating profit below current market expectations.
BASF chief executive Markus Kamieth again said a purchase of Evonik could make sense, but stressed the company would not pay an excessive price. According to people familiar with the transaction cited by dpa-AFX and dpa, BASF recently raised its offer to about €24 per share, or more than €11 billion in total.
BASF has not commented on the status of talks, citing confidentiality. The companies and Evonik’s largest shareholder, the RAG Foundation, disclosed in late September that there was a takeover offer.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.